SK Life Science Inc

General

Total Cases2
Active Cases2
Patents--
TypeOperating Company
Elite Ratings
--

Ratings

Experience
Grade
Trend
DCT
--
--
--
PTAB
--
--
--
CAFC
--
--
--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered
Case
Description
11/20/24
SUMMONS Returned Executed by SK Life Science, Inc., SK Biopharmaceuticals Co., Ltd..MSN Laboratories Private Limited served on 11/20/2024, answer due 12/11/2024. (Dellinger, Megan) (Entered: 11/20/2024)
11/20/24
SUMMONS Returned Executed by SK Life Science, Inc., SK Biopharmaceuticals Co., Ltd..MSN Pharmaceuticals Inc. served on 11/20/2024, answer due 12/11/2024. (Dellinger, Megan) (Entered: 11/20/2024)
11/19/24
Summons Issued as to MSN Laboratories Private Limited on 11/19/2024; MSN Pharmaceuticals Inc. on 11/19/2024. (Attachments: # [1] Summons Issued MSN Laboratories Private Limited)(scs) (Entered: 11/19/2024)
11/19/24
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent SK Inc. for SK Biopharmaceuticals Co., Ltd.; Corporate Parent SK Biopharmaceuticals Co., Ltd for SK Life Science, Inc. filed by SK Biopharmaceuticals Co., Ltd., SK Life Science, Inc.. (scs) (Entered: 11/19/2024)
11/19/24
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,654,133 B2. (scs) (Entered: 11/19/2024)
11/19/24
Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/08/2024. Date of Expiration of Patent: 06/16/2039.Thirty Month Stay Deadline: 9/10/2027. (scs) (Entered: 11/19/2024)
11/19/24
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (scs) (Entered: 11/19/2024)
11/19/24
COMPLAINT for ANDA/PATENT INFRINGEMENT filed against MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. ( Filing fee $ 405, receipt number ADEDC-4552266.) - filed by SK Life Science, Inc., SK Biopharmaceuticals Co., Ltd.. (Attachments: # [1] Exhibit A-B, # [2] Civil Cover Sheet)(scs) (Entered: 11/19/2024)
06/18/24
Summons Issued as to Aurobindo Pharma Limited on 6/18/2024; Aurobindo Pharma U.S.A., Inc. on 6/18/2024; Zenara Pharma Pvt. Limited on 6/18/2024. (Attachments: # 1 Summons Issued, # 2 Summons Issued)(mrr) (Entered: 06/18/2024)
06/18/24
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent SK Biopharmaceuticals Co., Ltd. for SK Life Science, Inc.; Corporate Parent SK Inc. for SK Biopharmaceuticals Co., Ltd filed by SK Biopharmaceuticals Co., Ltd, SK Life Science, Inc. (mrr) (Entered: 06/18/2024)